Purpose of review A collaboration of comparative effectiveness research trials of pulse oximeter saturation (SpO 2 ) targeting in extremely low-gestational-age neonates have begun to report their aggregate results. We examine the results of those trials, collectively referred to as the Neonatal Oxygenation Prospective Meta-analysis or NeOProM. We also discuss the uncertainties that remain and the clinical challenges that lie ahead.
INTRODUCTION
For the past 60 years, clinicians and researchers have been concerned about the safe use of supplemental oxygen in preterm infants, arguably the single most common therapeutic intervention in the neonatal ICU (NICU). Like warmth, water, and food, oxygen is vital to sustaining life, but in excess it can be harmful. Retinopathy of prematurity (ROP) first brought our attention to the harms of excess oxygen in the 1950s, but soon after, reports of increased rates of disability or death following oxygen restriction suggested that absolute oxygen restriction might also be harmful [1 && ]. What emerged was a need to better understand the risks at both ends of the oxygenation spectrum to find the optimal balance of competing adverse outcomes.
NEONATAL OXYGENATION PROSPECTIVE META-ANALYSIS: STUDY DESIGNS
In 2003, research clinicians and clinical trials experts from several countries conceived a plan to harmonize several planned comparative effectiveness research trials (CERTs) on oximeter saturation (SpO 2 ) targeting [2] . By designing CERTs with similar populations, methods and endpoints, the goal would be a prospective individual patient meta-analysis of the data from all trials. Five trials were designed under three study groups: the Benefits of Oxygen Saturation Targeting II (BOOST-II) trials, which included Australia, New Zealand, and the United Kingdom; the Canadian Oxygen Trial (COT); and the Surfactant, Positive Pressure and Pulse Oximetry Randomized Trial (SUPPORT) in the United States.
All five trials randomly assigned infants less than 28 weeks of gestation to one of two SpO 2 target ranges: a lower saturation group (85-89%) and a higher saturation group (91-95%) [3] [4] [5] . Blinding was maintained by using oximeters with software modification to read a 3% offset (either lower or higher) when in the SpO 2 range of 88-92%; clinicians were then instructed to target this range for all study infants. Alarm limits (as distinct from target ranges) were prespecified (COT), recommended (BOOST-II), or merely suggested (SUPPORT); for BOOST-II, the recommended alarm limits differed among the three trials. Targeting was initiated after initial stabilization but before 24 h of age; in one trial (SUPPORT), targeting was initiated before 2 h of age. In all trials, targeting continued until 36 weeks postmenstrual age or when the infant was in ambient air.
The primary outcome for each of the trials was a composite of death or disability by 18-24 months corrected age; SUPPORT also had a primary shortterm composite outcome of severe ROP or death before hospital discharge [5] . The Bayley Scales of Infant Development (BSID) were used to assess neurodevelopmental outcomes but the application of this tool differed among studies. Some of the centers in BOOST-New Zealand used the BSID-II, whereas all other centers used the BSID-III [6 && ,7] . As the BSID-III was known to underestimate disability compared with the BSID-II [8] , the New Zealand investigators used different cut-offs to define disability: 70 (À2 SD) for the BSID-II and 85 (À1 SD) for the BSID-III. Although the other four trials all used the BSID-III, SUPPORT used a cut-off of 70 to define disability [5] , whereas COT and the other two BOOST trials (Australia and United Kingdom) used 85, similar to BOOST-New Zealand. Secondary outcomes included intraventricular hemorrhage, necrotizing enterocolitis (NEC), bronchopulmonary dysplasia, and ROP; death was a prespecified secondary outcome only in the BOOST-II studies, but specific criteria (e.g., timing and cause) differed among the three BOOST study centers [4] .
NEONATAL OXYGENATION PROSPECTIVE META-ANALYSIS: REVISED PULSE OXIMETER ALGORITHMS
In early 2009, the BOOST-II investigators in the United Kingdom found an unexpectedly low frequency of SpO 2 readings in the range 87-90% among study subjects [9] . The oximeter manufacturer determined that this was due to a discontinuity in the calibration; they supplied revised software, but not before more than half of the BOOST-II study subjects, including all of the New Zealand subjects, had completed the targeting phase of the study. This change also occurred about midway in COT, but not in SUPPORT, as that trial had already been completed. Although not experienced by the COT investigators, the BOOST-II investigators reported improved SpO 2 targeting [10] ; this led them to specify a comparative analysis plan for subjects enrolled before and after pulse oximeter software revision.
NEONATAL OXYGENATION PROSPECTIVE META-ANALYSIS RESULTS: NO DIFFERENCES IN PRIMARY OUTCOMES
The first study to report a primary outcome was SUPPORT, and they found no difference between groups in the composite outcome of severe ROP or death before hospital discharge [5] . For the Neonatal Oxygenation Prospective Meta-analysis (NeOProM) primary outcome of death or disability by 2 years corrected age, neither SUPPORT nor COT found a difference between the two SpO 2 target groups [3, 11] . The BOOST-II investigators reported a significant difference between groups in the combined outcome of death or disability, but only when they excluded the New Zealand cohort [7] ; when all three BOOST-II trials are analyzed together, no difference in the primary outcome was found [12] . The BOOST-II investigators reported an unadjusted aggregate meta-analysis of all five trials showing an overall difference between SpO 2 groups in the primary outcome of death or disability [13 & ]. However, this did not take into account the different BSID cut-offs between SUPPORT and the other trials in defining disability; in separate meta-analyses using a uniform BSID cut-off and with additional data provided by the SUPPORT investigators, no difference in the primary outcome was found ( Fig. 1) [14, 15 && ].
KEY POINTS
SpO 2 is a poor estimator of tissue oxygenation.
Targeting SpO 2 is a balance of competing adverse outcomes.
Carefully conducted CERTs suggest that targeting an upper SpO 2 limit less than 90% may be harmful.
Individual (patient-level) data analyses from NeOProM are necessary to fully examine the relationship between SpO 2 and clinical outcomes.
It is unlikely that a single SpO 2 target range for the ELGAN will be clinically useful.
NEONATAL OXYGENATION PROSPECTIVE META-ANALYSIS RESULTS: SECONDARY OUTCOMES RAISE CONCERNS
At first blush, the careful planning and hard work of the NeOProM study teams have left us with a definitive conclusion, that targeting a SpO 2 of 91-95% versus 85-89% does not affect either the composite outcome of severe ROP or death, or the composite outcome of death or disability by 2 years corrected age. However, published analyses of secondary outcomes have cast doubt on the relative safety of a lower versus a higher SpO 2 target range. Concerns were raised when SUPPORT investigators noted significant but opposing trends in the two elements composing the primary outcome; death before discharge was more likely in the lower SpO 2 group, whereas severe ROP requiring treatment was more likely in the higher SpO 2 group. Although the difference in ROP might have been anticipated, the increase in mortality was not, but nevertheless suggested that oxygen targeting could represent a balance between competing adverse clinical outcomes.
The difference in mortality between study groups has prompted many NICUs to raise their SpO 2 target ranges for extremely low gestational age neonates (ELGANs), but some have advised caution in adopting this approach [16] . In a metaanalysis of outcomes before and after study oximeter software revision, differences in mortality were not seen among more than 3000 infants monitored with the original software [14, 15 && ]. Some have attributed the differences seen following the revised algorithm to better separation between study groups; however, post-hoc analyses show no improvement in study group separation following software revision [17] and no enhancement of treatment effect (mortality differences) among NICUs that achieved better separation [18 & ]. An additional confounder in interpreting the mortality results is that two of the BOOST-II trials were stopped early based on an interim analysis of mortality [10] , thus biasing the results toward this outcome; this may explain why these two trials show the largest differences in death between study groups in the NeOProM collaborative.
An explanation for the increased mortality in the lower SpO 2 group remains unclear. In all NeOProM trials, infants in the lower saturation group spent relatively more time with SpO 2 less than 85%, as might be expected; however, a systematic review could not demonstrate a relationship between time spent less than 85% and mortality [15 && ]. Also, when comparing the original with the revised oximeter data, a greater mortality difference was seen, although the amount of time infants spent less than 85% did not change [4] . Considering that the revised algorithm only affected readings between 87 and 91%, there may be modifying factors that place a subset of ELGANs at increased risk of mortality, even when subjected to only mild hypoxemia (SpO 2 85-89%); for example, post-hoc analyses of SUPPORT found that SGA but not AGA infants in the lower SpO 2 group were at increased risk of mortality [19, 20] . This concept needs to be further explored in the complete NeOProM dataset.
If there were no concerns for adopting the higher SpO 2 target range studied in the NeOProM trials, confirming a true mortality difference becomes less important. However, as might be expected based on past experience, and reaffirmed by a recent NeOProM meta-analysis [21] , the risk of severe ROP increases when a SpO 2 target range of 91-95% is imposed; indeed, a recent observational study from an NICU in Australia found that their rate of severe ROP more than doubled after they changed their SpO 2 target range from 88-92% to 91-95% [22 & ].
LIMITATIONS OF PULSE OXIMETRY
Pulse oximetry gives a rough estimate of arterial oxygen saturation (SaO 2 ) and hence arterial blood Oxygen saturation targeting by pulse oximetry Cummings and Lakshminrusimha oxygen content. The oximeter used in the NeOProM trials had a reported accuracy of AE3% (1 SD) [9, 23] ; this means that 5% of subjects would have an actual SaO 2 that is more than 6 points higher or lower than the reported SpO 2 . Although this degree of inaccuracy doesn't preclude its clinical usefulness for individual patients, it significantly limits the ability of pulse oximetry to discriminate between patients, or in the case of NeOProM, study group subjects. More importantly, peripheral SaO 2 , which pulse oximetry is designed to estimate, tells us nothing about what is going on at the tissue level in terms of perfusion and oxygen transfer. It is therefore unclear how SpO 2 targeting can be optimized to improve overall clinical outcomes. This weakness has been underscored in recent clinical studies in extremely preterm infants in whom near-infrared spectroscopy was used as a measure of cerebral tissue oxygen saturation (SctO 2 ), in conjunction with pulse oximetry. In studies of spontaneous desaturation episodes, SctO 2 was almost always maintained during peripheral desaturation, even when deep (SpO 2 < 70) or prolonged (>180 s) [24, 25] ; in another study, investigators found that hyperoxia assessed by SctO 2 but not SpO 2 correlated with development of severe ROP [26] . Although a useful adjunct for the management of infants who may require cardiorespiratory support, the utility of pulse oximetry in preventing oxygen-related tissue injury should be seriously questioned. Like the blind men trying to appraise the elephant, pulse oximetry gives us only one aspect of a complex situation and taken alone can lead us to false conclusions.
OPTIMAL OXIMETER SATURATION AS A 'MOVING TARGET'
The optimal SpO 2 for preterm infants has been described as a 'moving target', primarily because of the uncertainty that exists regarding the most appropriate range [27] . We would extend this argument, noting that it is physiologically implausible for a single SpO 2 target range to be 'optimal' for all preterm infants or even for a single preterm infant across the duration of a NICU stay. Newborn infants undergo dramatic developmental changes during the first weeks of life; some of these changes, like the transition from fetal to adult hemoglobin (which is often accelerated in the NICU setting by frequent transfusions) significantly alter the physiology of tissue oxygen transfer for any given SpO 2 [28] . Coming from a moderately hypoxic intrauterine environment, the newborn infant is likely to have residual tolerance to hypoxemia, at least during the early postnatal period [29] . Perhaps most importantly, the adverse outcomes we are trying to prevent (e.g., ROP and NEC) have different postnatal vulnerability periods; as the 'optimal' SpO 2 target is a balance between competing outcomes, differences in pathophysiologic timing for different adverse outcomes suggest that the optimal SpO 2 will also depend on postnatal and developmental age.
CONCLUSION
So how should we apply this information to clinical practice? We know that higher SpO 2 , especially during the first postnatal weeks, increases the risk of severe ROP; epidemiologic and biologic evidence to support this link is quite strong. The NeOProM trials further support that link but also suggest that lower SpO 2 increases the risk of NEC and death. In trying to reconcile these competing clinical outcomes, we note that the published results from the NeOProM collaboration seem to leave us with more questions than answers. Can we reconcile the differences between individual trials? How reliable are outcome differences in light of the tremendous overlap in SpO 2 distributions between the two study groups? Why didn't better separation between study groups lead to larger treatment effects? What is the effect on a secondary outcome measurement when trials are stopped early for evidence of benefit in that secondary outcome? Are there patient characteristics that affect the risk of either a lower or higher SpO 2 target? Why was there such a dramatic change in treatment effect in some centers after using oximeters with the revised software? Is there biologic plausibility for an increased risk of adverse outcomes for modest (87-90%) but not moderate (<85%) hypoxemia? Can targeting SpO 2 optimize clinical outcomes?
We must be careful when interpreting the results from NeOProM. Although the collective results from these trials support using an SpO 2 target range of 91-95% compared with 85-89%, they give us no guidance about any other target range. In particular, given the high degree of overlap between study groups, as well as the significant deviation beyond the specified target ranges, it is possible that a wider target range that partially (or even totally) encompasses both study group ranges may be associated with similar outcomes. For example, although it seems prudent to avoid a target range of 85-89%, that does not mean that a target range of 86-94% would not be preferable to 91-95%. It is interesting to note that the European Consensus Guidelines chose a target SpO 2 range of 90-94% for preterm infants with respiratory distress syndrome after evaluating the NeOProM results; they also noted that this was a weak recommendation based on the quality of evidence [30 && ]. It may also make physiologic sense to titrate SpO 2 target ranges based on individual patient characteristics, such as gestational age, postmenstrual age, and transfusion status; some have embraced this concept of a 'moving target' for SpO 2 [31] .
The NeOProM trials also give us insight into narrower target ranges, not just different target ranges. These trials suggest that narrowing the target range increases the time spent outside that range; infants in NeOProM were only within target about 50% of the time. This tendency to stray outside narrowly confined target ranges may explain the increased risk of severe ROP in the higher SpO 2 target group (which spent relatively more time above 95%) and the increased mortality in the lower SpO 2 target group (which spent relatively more time below 85%). If a wider SpO 2 target range, say 87-95%, were allowed, it is likely that infants would spend less time either below 85% or above 95%, compared with infants in the lower and higher target groups of the NeOProM, respectively.
A detailed individual patient data analysis of the NeOProM trials, wherein individual infant outcomes are correlated with their actual SpO 2 frequency distributions, regardless of target group assignment, is sorely needed as it could shed light on many of the questions raised above. This was the goal of NeOProM, and we eagerly await these analyses. However, we remain skeptical that a single, optimal SpO 2 target for the extremely low-gestational-age infant will be clinically useful. Rather, efforts should be directed at minimizing supplemental oxygen exposure, reducing wide fluctuations in oxygenation, and eliminating alarm fatigue -factors known to be associated with poorer outcomes. Advances in avoiding oxygen-related organ injury, either from too little or too much, will come from reliable methods to assess tissue oxygenation in the clinical setting and a better understanding of the pathophysiology of oxygenrelated organ injury in this highly vulnerable population.
